In: In vivo CAR-T

RXIM002

RiboX Therapeutics

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Early Phase 1 trial completes
Trials
2 active
2 in total
Targets
 

What this is

How it works
Reprograms the patient's own immune T cells, inside the body, to hunt one kind of cell, such as cancerous B cells. Standard CAR-T does this in a lab.In vivo CD19 CAR, circular RNA in targeted lipid nanoparticles
How it’s given
“Targeted lipid nanoparticle (tLNP)-delivered circular ribonucleic acid (circRNA) encoding an anti-human CD19 chimeric antigen receptor (CAR)”In the company’s words, NCT07765966 on ClinicalTrials.gov
Tested for
Immune Thrombocytopenia (ITP), Relapsed/Refractory B Cell-Mediated Autoimmune Diseases
Main trialPhase 1
“The Phase 1 is to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of RXIM002 in patients with relapsed or refractory autoimmune cytopenias.”In the company’s words, NCT07765966 on ClinicalTrials.gov

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 1Not yet recruiting 30 Jun 2028 Phase 1 Dose Escalation Study of RXIM002 in Autoimmune Cytopenias
Early Phase 1Recruiting 19 Dec 2027 Safety and Efficacy Study of RXIM002 in Severe, Relapsed or Refractory Autoimmune Diseases
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 16 Nov 2026 · EU trials register (CTIS) updated 16 Nov 2026 · openFDA updated 13 Nov 2026

Follow RXIM002

Following is part of Solo: you see every change to RXIM002 the day it happens.

Solo

$49a month

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in